-Fatty liver and drugs

Antonio Grieco, Alessandra Forgione, Luca Miele, Vittoria Vero, Av Greco, Antonio Gasbarrini, Giovanni Battista Gasbarrini

Risultato della ricerca: Contributo in rivistaArticolo in rivista

56 Citazioni (Scopus)


Abstract Drug-induced liver diseases (DILD) are clinico-pathologic patterns of liver injury caused by drugs or other foreign compounds. Steatohepatitis is a rare form of DILD, and drugs account for fewer than 2% of non-alcoholic steatohepatitis (NASH). Drugs known to be capable of inducing steatosis and steatohepatitis can be divided into three broad groups: those that cause steatosis and steatohepatitis independently (e.g., amiodarone, perhexiline maleate); drugs which can precipitate latent NASH (e.g., tamoxifen); drugs whic duce sporadic events of steatosis/steatohepatitis (e.g., carbamazepine). Clinical DILD syndromes include acute viral hepatitis-like injury, acute liver failure, cholestatic hepatitis,liver disease with signs of hypersensitivity, autoimmune hepatitis-like injury, acute venous-Outflow obstruction, chronic cholestasis, ciirrhosis, steatosis and steatohepatitis. The clinical picture is by no means dependent on the mechanism of injury (direct hepatotoxicity, idiosyncratic reactions, hypersensitivity reactions). Reliable diagnosis of drug-induced liver disease requires demonstration of close correlation between the patient history and clinical, laboratory, and histological data.
Lingua originaleEnglish
pagine (da-a)261-263
Numero di pagine3
RivistaEuropean Review for Medical and Pharmacological Sciences
Stato di pubblicazionePubblicato - 2005


  • Fatty liver


Entra nei temi di ricerca di '-Fatty liver and drugs'. Insieme formano una fingerprint unica.

Cita questo